Results for reverse mutation translation from English to Slovenian

reverse mutation system
bakterijski test povratnih mutacij

baseline reverse transcriptase mutation
izhodišče mutacija reverzne transkriptaze

mutagenicity - reverse mutation test bacteria
mutagenost — preizkus povratne mutacije pri bakterijah

mutagenicity: reverse mutation test using bacteria
mutagenost – test povratne mutacije pri bakterijah

mutagenicity (escherichia coli - reverse mutation assay)
b.13 mutagenost (escherichia coli – preskus povratne mutacije)

mutagenicity (salmonella typhimurium - reverse mutation assay)
b.14 mutagenost (salmonella typhimurium – preskus povratne mutacije)

mutagenicity (escherichia coli - reverse mutation assay) //157
mutagenost (escherichia coli – preskus povratne mutacije) 414

mutagenicity (salmonella typhimurium - reverse mutation assay) //160
mutagenost (salmonella typhimurium – preskus povratne mutacije) 417

b.13/14. mutagenicity: reverse mutation test using bacteria
b.13/14 mutagenost: preizkus povratne mutacije pri bakterijah

several procedures for performing the bacterial reverse mutation test have been described.
opisanih je nekaj postopkov za izvedbo preizkusa bakterijskih povratnih mutacij.

the bacterial reverse mutation test is rapid, inexpensive and relatively easy to perform.
preizkus bakterijskih povratnih mutacij je hiter, poceni in relativno lahko izvedljiv.

dm1 was not mutagenic in an in vitro bacterial reverse mutation (ames) assay.
dm1 in vitro ni bil mutagen v bakterijskem preizkusu reverzne mutacije (amesov test).

crizotinib was not mutagenic in vitro in the bacterial reverse mutation (ames) assay.
krizotinib ni deloval mutageno in vitro pri preskusu bakterijske reverzne mutacije (amesov preskus).

this method is a replicate of the oecd tg 471, bacterial reverse mutation test (1997).
ta metoda ustreza metodi oecd tg 471, bacterial reverse mutation test (1997).

the substance should be examined in a bacteriological (reverse mutation) test with and without metabolic activation.
snov je treba pregledati z bakteriološkim preskusom (povratna mutacija), z metabolično aktivacijo ali brez nje.

on the other hand, factors which enhance the sensitivity of the bacterial reverse mutation test can lead to an overestimation of mutagenic activity.
po drugi strani pa lahko dejavniki, ki povečajo občutljivost preizkusa bakterijskih povratnih mutacij, privedejo do precenitve mutagenega delovanja.

annex to regulation (ec) no 440/2008, method b 13/14 — reverse mutation test using bacteria,
metoda b13/14 iz priloge k uredbi (es) št. 440/2008 – testi reverzne mutacije na bakterijah,

forward or reverse mutation studies using eukaryotic micro-organisms (saccharomyces cerevisiae) (method b.15)
napredne ali povratne mutacijske študije z uporabo evkariotskih mikroorganizmov (saccharomyces cerevisiae) (metoda b.15)

atazanavir was negative in an ames reverse-mutation assay but did induce chromosomal aberrations in vitro in both the absence and presence of metabolic activation.
amesov test reverznih mutacij je bil za atazanavir negativen, toda in vitro so odkrili pojav kromosomskih aberacij, in sicer tako s presnovno aktivacijo kot brez nje.

carfilzomib was not mutagenic in the in vitro bacterial reverse mutation (ames) test and was not clastogenic in the in vivo mouse bone marrow micronucleus assay.
karfilzomib ni bil mutagen v preizkusu bakterijskih reverznih mutacij (amesov test) in vitro, in vivo pa ni bil klastogen v mikrojedrnem preizkusu na kostnem mozgu miši.